Outcome of Board Meeting

29th October 2026 The Secretary, The Secretary, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Dalal Street, Bandra-Kurla Complex, Bandra (E), Mumbai 400 001 Mumbai 400 051 Scrip Code: 500674 Symbol: SANOFI Sub: Outcome of the Board Meeting of the Company held on Thursday, 29th October 2026 Dear Sir / Madam, Further to our intimation dated 19th October 2026, we wish to inform you that the Board of Directors, at its meeting held today i.e. Thursday, 29th October 2026, inter-alia considered and • Approved the Unaudited Financial Results for the quarter and nine months ended 30th September 2026. Accordingly, we enclose a copy of the Limited Review Report, and the Unaudited Financial Results for the quarter and nine months ended 30th September 2026 as required under Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”). A press release in this regard has also been enclosed. An extract of the aforesaid Financial Results will be published in the newspapers in the format prescribed under Regulation 47 of the Listing Regulations. • Declared an Interim Dividend of Rs. 75/- (Rupees Seventy-Five only) per equity share of the face value of Rs. 10/- (Rupees Ten only) each for the financial year 2026, which shall be paid within the stipulated timelines. Pursuant to Regulation 42 of the Listing Regulations, the Company has fixed Thursday, 5th November 2026 as the “Record Date” for the payment of Interim Dividend to those Members whose names are on the Company’s Register of Members on Thursday, 5th November 2026 and those whose names appear as Beneficial Owners as at the close of the business hours on Thursday, 5th November 2026 as per the details to be furnished by the Depositories, viz. NSDL and CDSL, for this purpose. The Financial Results are being made available on the Company’s website on Financial results - Sanofi India. Sanofi India Limited, Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 - India - Tel.: +91(22) 2803 2000 - Fax: +91(22) 2803 2939 Corporate Identity Number: L24239MH1956PLC009794 Website: www.sanofiindialtd.com | www.sanofi.in Email: igrc.sil@sanofi.com The meeting of Board of Directors commenced at 2:30 p.m. and concluded at 4:45 p.m. Please take the above information on record. Thanking you, Yours faithfully For Sanofi India Limited Haresh Vala Company Secretary and Compliance Officer Membership No.: A18246 Encl:a/a 1. MUFG Intime India Private Limited, Registrar and Share Transfer Agent 2. National Securities Depository Limited (“NSDL”) 3. Central Depository Services (India) Limited (“CDSL”) Sanofi India Limited, Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 - India - Tel.: +91(22) 2803 2000 - Fax: +91(22) 2803 2939 Corporate Identity Number: L24239MH1956PLC009794 Website: www.sanofiindialtd.com | www.sanofi.in Email: igrc.sil@sanofi.com Press Release Sanofi India delivers strong Q3 2026 performance, led by 9% growth in Diabetes Portfolio resulting in robust profit momentum Mumbai, October 29th, 2026 Sanofi India Limited announced its financial results for the quarter ended on September 30th, 2026, reporting domestic net sales growth of +2% and total net sales growth of 4% compared to the third quarter of 2025. The Insulin portfolio extended its winning run, delivering high single-digit growth of 9% in Q3’26 cementing Sanofi's leadership in the Diabetes Injectable segment with a 55% market share. Lantus®, Toujeo®, and Apidra® led the charge, joined by the strong performance of Soliqua®, the premium offering in the premix diabetes space. The public sector business surged by 85%, driven by new accounts opened for innovative analogue segments, further deepening Sanofi's footprint in the diabetes injectable space. Export sales delivered good double-digit growth on the back of a winning strategy, underscoring the resilience of Sanofi India's international operations amid global headwinds. Strategic partnerships in the Cardiovascular, Oral anti-Diabetes and Central Nervous System segments are progressing and have contributed to incremental market reach. Partnership revenues were broadly stable in Q3 2026, with the expanded commercial footprint showing an acceptable return on investment, while continued focus is needed to strengthen performance. Profits before tax and exceptional items rose 22% to INR 158 crores, compared to INR 130 crores in the third quarter of 2025. Profit before tax as a percentage of net sales improved to 34% in Q3 2026, up from 29% in Q3 2025. This gross margin improvement reflects a favorable product mix, a one-off reversal of provisions, and disciplined cost management through operational efficiencies, with operating expenses (employee cost + other expenses) declining 8% compared to the third quarter of 2025. Deepak Arora Managing Director "Our diabetes business is firmly in momentum, growing in double digits quarter-on- quarter (at a YTD-level). Sanofi India's PAT has also grown in double digits (at a YTD- level), capped by a strong Q3'26 PAT growth of 54% v/s Q3'25. These results reflect a laser-focused strategy that keeps patients at the center of every decision we make. Our acceleration in the public sector shows that we are not just growing, we are widening access to innovative therapies across the country. With a 55% value share, a growth of 14% in YTD 2026, and a modernized go-to- market model, our diabetes injectable segment is setting the foundation for sustainable, long-term value creation for the times to come. As we celebrate 70 years of Sanofi in India, we remain committed to giving back to our communities through educational, awareness, diagnostic, and capability-building initiatives. Our KIDS Program (Kids & Diabetes in School) has reached 3500+ schools to date, educating 6,00,000 children across Goa, Uttar Pradesh & Madhya Pradesh (MP). Over the last quarter, the KiDS program was piloted in 2 districts (Berasia & Phanda) of Bhopal (MP) and through 2026, our aim is to train 600+ teachers & ~40,000+ children in understanding diabetes and living a healthy lifestyle. Furthermore, our Medical Mobile Units continue to raise health awareness, as they are screening for Non-Communicable Diseases (NCDs namely diabetes, hypertension & oral cancer), providing education, screening, diagnosis, free-of-cost treatment and giving timely referrals to government health centers; having touched the lives of 7,80,000 beneficiaries across 11 districts of Maharashtra." Sanofi in India Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people’s lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building. Sanofi’s India Charitable Access Program (InCAP) is the country’s longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company’s global pipeline. Sanofi India’s world-class manufacturing site in Goa produces for people in India and 24+ other countries. Sanofi has located one of its Global Capability Center in Hyderabad, India, which serves as a global talent hub, providing a broad range of services across Sanofi’s worldwide operations. Sanofi (India) is a certified ‘Great Place to Work’ (2026-2027) and is recognized by the ‘Top® Employers Institute’ – a global authority that honours excellence in people practices from 2019- 2024. Sanofi’s local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL). For more information, visit: www.sanofi.com/en/india, LinkedIn and [Showing first 8,000 characters — download PDF for full document]